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Objectives: Many initiatives (e.g., PROTECT, EFSPI) are exploring quantitative meth-
odologies to conduct benefit/risk assessments of medicines. Objectives of this study 
were to combine quantitative methodologies that can capture expert knowledge 
and decisionmakers insights to genuinely support real-world decisions. MethOds: 
Using the case study of efalizumab, approved by the EMA in 2004 for the treatment 
of plaque psoriasis and withdrawn in 2009, a pragmatic methodology was developed 
that combines advanced pharmacoepidemiology and MCDA for quantitative benefit/
risk assessment. Development involved application of: MCDA principles to ensure 
applicability to any therapeutic area, comparability across medicines, and portabil-
ity over product cycle (re-evaluation); and advanced pharmacoepidemiology and 
Bayesian modeling to identify/generate most useful data. Overarching design was 
guided by ethical implications of criteria and data selection as well as applicability in 
real life settings including face validity, time constraints, complexity and transpar-
ency. Results: The hierarchical multicriteria model consists of two major domains: 
Benefits (favourable effects, covering the criteria Clinical efficacy/effectiveness and 
Patient Reported outcomes); and Risks (unfavourable effects – criterion Safety). The 
safety criterion is subdivided into three generic subcriteria (Adverse events, Serious 
AEs and Fatal AEs). The benefit criteria are subdivided into specific subcriteria that 
correspond to the most relevant outcomes for a treatment for plaque psoriasis. All 
performance are assigned relative to existing alternatives or placebo. Each subcri-
terion contributes to the output of the model, the Benefit/Risk Estimate, which is 
the sum of normalized weights for each subcriterion multiplied by the respective 
performance score. Pharmacoepidemiology data is provided in a standardized for-
mat for each subcriterion and includes meta-analytic comparative statistics based 
on clinical trials, observational data and Bayesian models. Uncertainty is explored 
in sensitivity analyses. cOnclusiOns: Integration of pragmatic MCDA modeling 
with advanced pharmacoepidemiology allows quantitative benefit/risk assessment 
that can be applicable and meaningful in real life regulatory settings.
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Objectives: The Center for Translational Molecular Medicine (CTMM) is a multi-
million public-private partnership, including universities, academic hospitals, phar-
maceutical and medical technology companies. CTMM aims to accelerate molecular 
diagnostics and imaging technologies to enable determination of predisposition, 
early diagnosis, and personalized treatment of patients. It is unique in that it man-
dates early Health Technology Assessment (HTA) in each of its 21 projects. This study 
assessed the impact of CTMM on scientific, translational, clinical and economic 
aspects. MethOds: The impact assessment was guided by the “Research Impact 
Framework” (Kuruvilla 2006) Objective data were gathered from extensive CTMM 
administrations, including publications, patents, project proceedings, early HTA 
results, etc. Perceived impact was investigated using a CTMM-wide survey (n= 167) 
and two focus groups. Results: CTMM focuses its impact on disease areas with 
high Disability Adjusted Life Years and high societal costs, i.e. oncology, cardiovas-
cular, neurologic, infection and immunity diseases. Its scientific impact is as high 
as the overall impact of Dutch biomedical research, i.e. 15%-80% above international 
volume and journal impact standards. CTMM is perceived to stimulate and acceler-
ate translation of technology to the clinic, with a median score of 4 out of 5 (IQR 
3-5). Its main strength lies in pre-clinical and phase 1 development (median score 
4 of 5; IQR 4-5). CTMM has generated nearly 1900 FTE of translational R&D capacity 
between 2008-15. Experience with and impact of early HTA varies widely between 
projects (median score 3 of 5; IQR: 2-4). CONCLUSION: By facilitating and managing 
effective and safe public-private collaboration, CTMM has demonstrated a solid sci-
entific impact. Its impact on translational, (future) clinical and economic aspects is 
generally perceived as large. Metrics to objectively measure this need improvement 
as well as longer follow-up. The early HTA analyses have provided critical insights 
and exemplar approaches for future early HTA work in public-private partnerships.
PHP129
HOw TO cOnsider equiTy in decisiOns TO incOrPOrATe new 
TecHnOlOgies in brAziliAn unified HeAlTH sysTem (sus)?
Pereira V.C.1, Silva E.2, Biella C.1, Santos V.C.C.1, Petramale C.1
1Brazilian Ministry of Health, Brasília-DF, Brazil, 2Brasília University, Brasília, DF, Brazil
Objectives: In 2011 was published 12.401 Law establishing the National Committee 
for Technologies Incorporation in SUS (CONITEC) and defining the criteria and dead-
lines for the analysis and adoption of technologies. According to the law, CONITEC’s 
assessment must considers necessarily scientific evidences about efficacy, accuracy, 
effectiveness and safety of technologies and economic evaluation studies of ben-
efits and costs in relation to the technologies already incorporated in SUS. Studies 
of economic evaluation traditionally ignore equity in health, and because this gap, 
researches have been undertaken to develop methods to incorporate equity into 
economic evaluation in health. Thus, this paper aims to analyze the viability of 
using an economic evaluation framework in the decision making process about 
incorporating technologies so that the equity is maximized within the Brazilian 
Unified Health System. MethOds: To fulfill this goal, review the scientific lit-
erature for methods to incorporate equity into cost-effectiveness was conducted 
with subsequent discussion how the methods found can be applied in the con-
text of SUS, a system that offers universal coverage to approximately 201 million 
citizens. Results: Until end of 2013, CONITEC recommended the incorporation of 
64 technologies for diagnosis, prevention and treatment of various diseases, and 
no study of economic evaluation submitted addressed the issue of equity. By the 
research found a systematic review conducted by Johri & Norheim (2012) having 
found three distinct approaches: integration of distributional concerns through 
equity weights and social welfare functions, exploration of the opportunity costs 
of alternative policy options, through mathematical programming and multi-cri-
aspect of the pharmaceutical industry. After the reform policy in 1978, both the 
governmental regulators and the regulated pharmaceutical industry became devel-
opment-oriented. The effective control of the quality and safety of pharmaceutical 
products became a serious problem. In order to reverse the situation China tried 
to establish an independent drug regulatory system. cOnclusiOns: Because of 
path dependence it is very difficult to turn the drug regulatory system from the sys-
tem of unification of the regulators and the regulated into an independent system. 
The introduction of a formally independent regulatory system has improved the 
regulator’s motive to supervise the quality and safety of drugs to some extent. But 
many impediment factors still exist both inside and outside China’s drug regula-
tory system. The great difficulties to establish an effective drug regulatory system 
China experienced during the past 10 years proved that the old way in which the 
government regulatory agencies operate is very difficult to shake. The policy maker 
should fully understand the impact of the previous system and make a long and 
Coordinative effort. The best way to establish a good independent drug regulatory 
system has to be a gradual rather than a radical reform.
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Objectives: The Brazilian Public Health System (SUS) was established in 1988, 
thereby ensuring that the citizen universal right to health, having as one of its 
principles to the participation or social control. The performance of the SUS in the 
field of evaluation and incorporation of new technologies represents the public 
interest as defined by universal policies are committed to the equity and based on 
scientific knowledge consistent. The year of 2011 represented a breakthrough in 
transparency and social participation in the process of incorporating technology 
with the publication of Law no. 12,401, of 28/04/2011, which has set up a National 
Commission for the Incorporation of Technology in the SUS/CONITEC. The aim of 
this study was to identify in the participation of public consultations of CONITEC, 
the civil society participation, public and private institutions. MethOds: This is a 
descriptive, cross-sectional study, which was developed from the analysis of tech-
nical reports of Conitec which related to public consultation by the committee 
were extracted data to support decision-making on technology incorporation in 
SUS. Results: In the years 2012 and 2013, 78 public consultations and more than 
4,182 contributions were examined by CONITEC published arising from health care 
institutions, patient association, educational institutions, medical societies, etc, that 
recommended to incorporate 64 new technologies in the SUS. cOnclusiOns: The 
Ministry of Health, responsible for enforcement of the law n. 12.401, use system-
atically the public consultations as the instrument to gather contributions from 
segments of society in their process work. To the extent that such participation 
is intended to subsidize the decision about incorporating technology in the SUS, 
there are significant gains in building the public policy agenda, adding legitimacy 
and transparency in government decision-making.
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Objectives: The Brazilian public health system ensures universal, equitable and 
comprehensive access to health technologies, including medicines. The high-cost 
medicines are offered through Specialized Pharmaceutical Services Component 
(SPSC). The clinical conditions treated in the SPSC are defined in the Guidelines in 
the form of lines of care. To describe the experience and results of the SPSC with its 
particular strategies in the quest for the comprehensive health care. MethOds: 
Focused on the SPSC’s issues, we did a retrospective data analysis related to its 
management strategies for the pharmaceutical services in the public health sys-
tem in the period 2010 to 2013. Data were obtained from documents of the Ministry 
of Health in 2013 (current values; exchange rate: US$ 1 = R$ 2.30). Results: As 
a strategy to increase medicines access and optimization of resource allocation, 
the MoH expanded the amount of centralized procurement medicines, from 13 
to 51 products. This deed was focused on those medicines with a concentrated 
market. As a consequence, this action allowed a saving of U$ 403.8 million in four 
years, compared to the price in 2010. The medicines that most contributed to the 
economy were adalimumabe (U$120 million), etanercepte (U$100 million) and 
infliximab (U$44 million). Betainterferona (52%), etanercepte (48%), imiglucerase 
(48%), adalimumabe (37%) e Alfapeginterferona (37%) were the products with a 
greater reduction in the unit price, considering the accumulated value at period. 
The increase in the number of units distributed was 263%. cOnclusiOns: The 
SPSC was designed in 2010 for the budgetary resources optimization and to expand 
access to medicines for diseases that require complex health services or high-cost 
medicines. The purchasing power of the MoH is a strategy that allowed expansion 
of access to medicines, with optimization of budgetary resources in the Brazilian 
public health system.
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